Tempus AI Reports Strong Q2 2025 Results, Driven by AI-Powered Genomics and Data Services

Tempus AI Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Tempus AI (NASDAQ:TEM)

Tempus AI, Inc. TEM will release earnings results for the second quarter before the opening bell on Friday, Aug. 8. Analysts expect the Chicago, Illinois-based company to report a quarterly loss at 25 cents per share, versus a year-ago loss of 63 cents per share. Tempus AI projects to report quarterly revenue at $297.76 million, compared to $165.97 million a year earlier, according to data from Benzinga Pro. On July 16, Tempus AI announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software. Tempus AI shares gained 5.8% to close at $58.74 on Thursday. Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables. Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period. Trending Investment OpportunitiesAdvertisementArrivedBuy shares of homes and vacation rentals for as little as $100. Get StartedWiserAdvisorGet matched with a trusted, local financial advisor for free.Get StartedPoint.comTap into your home's equity to consolidate debt or fund a renovation.Get StartedRobinhoodMove your 401k to Robinhood and get a 3% match on deposits.Get Started Piper Sandler analyst David Westenberg maintained a Neutral rating and increased the price target from $55 to $70 on May 15, 2025. This analyst has an accuracy rate of 63%. Needham analyst Ryan MacDonald reiterated a Buy rating with a price target of $70 on May 7, 2025. This analyst has an accuracy rate of 62%. BTIG analyst Mark Massaro initiated coverage on the stock with a Buy rating and a price target of $60 on April 21, 2025. This analyst has an accuracy rate of 72%. JP Morgan analyst Rachel Vatnsdal downgraded the stock from Overweight to Neutral and raised the price target from $50 to $55 on Feb. 25, 2025. This analyst has an accuracy rate of 66%. TD Cowen analyst Dan Brennan reinstated a Buy rating with a price target of $74 on Feb. 5, 2025. This analyst has an accuracy rate of 63% Considering buying TEM stock? Here's what analysts think: Read This Next: Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate With Over 7% Dividend Yields Photo via Shutterstock TEMTempus AI Inc$60.559.04%Stock Score Locked: Edge Members Only Benzinga Rankings give you vital metrics on any stock - anytime. Unlock RankingsEdge RankingsMomentum65.31GrowthN/AQualityN/AValue15.38Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Earnings Outlook For Tempus AI - Tempus AI (NASDAQ:TEM)

Tempus AI TEM is gearing up to announce its quarterly earnings on Friday, 2025-08-08. Here's a quick overview of what investors should know before the release. Analysts are estimating that Tempus AI will report an earnings per share (EPS) of $-0.34. The announcement from Tempus AI is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter. It's worth noting for new investors that guidance can be a key determinant of stock price movements. Past Earnings Performance Last quarter the company beat EPS by $0.03, which was followed by a 12.59% increase in the share price the next day. Here's a look at Tempus AI's past performance and the resulting price change: Market Performance of Tempus AI's Stock Shares of Tempus AI were trading at $55.53 as of August 06. Over the last 52-week period, shares are up 47.64%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. Insights Shared by Analysts on Tempus AI For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Tempus AI. The consensus rating for Tempus AI is Neutral, based on 5 analyst ratings. With an average one-year price target of $69.6, there's a potential 25.34% upside. Peer Ratings Comparison The analysis below examines the analyst ratings and average 1-year price targets of Revvity, Bio-Techne and Medpace Hldgs, three significant industry players, providing valuable insights into their relative performance expectations and market positioning. Analysts currently favor an Outperform trajectory for Revvity, with an average 1-year price target of $112.5, suggesting a potential 102.59% upside. Analysts currently favor an Buy trajectory for Bio-Techne, with an average 1-year price target of $68.8, suggesting a potential 23.9% upside. Analysts currently favor an Neutral trajectory for Medpace Hldgs, with an average 1-year price target of $410.88, suggesting a potential 639.92% upside. Analysis Summary for Peers In the peer analysis summary, key metrics for Revvity, Bio-Techne and Medpace Hldgs are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance. Key Takeaway: Tempus AI ranks at the bottom for Revenue Growth among its peers. It also has the lowest Gross Profit margin. In terms of Return on Equity, Tempus AI is positioned at the bottom as well. Overall, compared to its peers, Tempus AI lags behind in key financial metrics. Unveiling the Story Behind Tempus AI Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. Tempus AI: Financial Performance Dissected Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity. Revenue Growth: Tempus AI's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 75.38%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector. Net Margin: Tempus AI's net margin is impressive, surpassing industry averages. With a net margin of -26.6%, the company demonstrates strong profitability and effective cost management. Return on Equity (ROE): Tempus AI's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -35.57%, the company may face hurdles in generating optimal returns for shareholders. Return on Assets (ROA): Tempus AI's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.51%, the company may encounter challenges in delivering satisfactory returns from its assets. Debt Management: Tempus AI's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.63, the company relies more heavily on borrowed funds, indicating a higher level of financial risk. To track all earnings releases for Tempus AI visit their earnings calendar on our site. This article was generated by Benzinga's automated content engine and reviewed by an editor. TEMTempus AI Inc$57.243.08%Stock Score Locked: Edge Members Only Benzinga Rankings give you vital metrics on any stock - anytime. Unlock RankingsEdge RankingsMomentum65.31GrowthN/AQualityN/AValue15.38Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Where Tempus AI Stands With Analysts - Tempus AI (NASDAQ:TEM)

Ratings for Tempus AI TEM were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $70.2, a high estimate of $75.00, and a low estimate of $68.00. This current average reflects an increase of 16.61% from the previous average price target of $60.20. Interpreting Analyst Ratings: A Closer Look An in-depth analysis of recent analyst actions unveils how financial experts perceive Tempus AI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tempus AI. This offers insight into analysts' perspectives on the current state of the company. Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Tempus AI compared to the broader market. Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Tempus AI's stock. This comparison reveals trends in analysts' expectations over time. To gain a panoramic view of Tempus AI's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table. Stay up to date on Tempus AI analyst ratings. All You Need to Know About Tempus AI Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. Tempus AI: Delving into Financials Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity. Revenue Growth: Tempus AI's revenue growth over a period of 3M has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 89.57%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers. Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -13.62%, the company may need to address challenges in effective cost control. Return on Equity (ROE): Tempus AI's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -13.48%, the company may encounter challenges in delivering satisfactory returns for shareholders. Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.7%, the company may need to address challenges in generating satisfactory returns from its assets. Debt Management: Tempus AI's debt-to-equity ratio surpasses industry norms, standing at 2.76. This suggests the company carries a substantial amount of debt, posing potential financial challenges. Understanding the Relevance of Analyst Ratings Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions. In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs. Which Stocks Are Analysts Recommending Now? Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market. This article was generated by Benzinga's automated content engine and reviewed by an editor. TEMTempus AI Inc$61.100.46%Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock - anytime. Reveal Full ScoreEdge RankingsMomentum79.56GrowthN/AQualityN/AValue14.99Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Why Is Tempus AI Stock Soaring Friday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc. TEM reported second-quarter financial results Friday. The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, beating analyst estimates for a loss of 24 cents per share. Tempus AI reported quarterly revenue of $314.64 million, beating the consensus estimates of $296.85 million. Revenue increased 89.6% year-over-year. Genomics contributed $241.8 million in revenue in the quarter, growing 115.3% year over year. Also Read: Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out Oncology testing (Tempus genomics) delivered $133.2 million of revenue, up 32.9%, with approximately 26% volume growth versus 20% last quarter. Hereditary testing sales (Ambry genetics) reached $97.3 million, up 33.6% year-over-year on a pro forma basis with approximately 32% volume growth. Revenue from Data and services totaled $72.8 million, delivering 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), which grew 40.7% year-over-year. Adjusted EBITDA of ($5.6 million) in the second quarter of 2025 compared to ($31.2 million) in the second quarter of 2024, an improvement of $25.6 million year-over-year. "The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis," said Eric Lefkofsky, Founder and CEO of Tempus. "We saw significant re-acceleration of our clinical volumes, which grew 30% in the quarter, as we delivered more than 212,000 NGS tests," Lefkofsky said in a statement on Friday. Database Update Through more than 4,500 integrations, Tempus said it connected to more than 40 million clinical patient records, with around 9 million de-identified and ingested, spanning approximately 1.1 billion healthcare documents, a significant percentage of which are connected to the around 4 million samples the company has sequenced. As a result, the company's database stands at over 350 petabytes of connected clinical and molecular data. Tempus AI ended the quarter with $293.0 million in cash and marketable securities, an improvement of around $70 million over last quarter. Outlook Tempus AI increased its guidance and expects a full year of 2025 revenue of approximately $1.26 billion for the consolidated business, representing approximately 82% annual growth, compared to the consensus of $1.25 billion. Earlier, the company expected revenue between $1.24 billion and $1.25 billion for its consolidated Tempus and Ambry Genetics business. The company reaffirms full-year 2025 adjusted EBITDA of $5 million, an improvement of approximately $110 million over 2024. Tempus AI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software in July. Tempus said the FDA granted it 510(k) clearance for its Tempus ECG-Low EF software, which uses AI to identify patients with a potential left ventricular ejection fraction. Price Action: Tempus AI shares were up 5.79% after hours, trading at $55.21 at the time of publication on Tuesday. Read Next: Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills Photo by Piotr Swat via Shutterstock TEMTempus AI Inc$64.169.23%Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock - anytime. Reveal Full ScoreEdge RankingsMomentum65.31GrowthN/AQualityN/AValue15.38Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Tempus AI (TEM) Q2 Revenue Surges 90%

Tempus AI (TEM 5.78%), a technology company that applies artificial intelligence to precision diagnostics and healthcare data, reported its Q2 2025 earnings on August 8, 2025. The period was marked by rapid growth and strong performance across its genomics and data services businesses. Revenue (GAAP) climbed to $314.6 million, surpassing the analyst consensus of $297.8 million. The non-GAAP loss per share narrowed to ($0.22), better than the expected ($0.23). Management lifted its full-year 2025 revenue forecast to $1.26 billion and now expects adjusted EBITDA profitability for fiscal 2025. The quarter reflected accelerating commercial momentum, significant margin expansion, and ongoing progress leveraging AI and data partnerships. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Business Overview and Recent Focus Tempus AI seeks to transform healthcare by using artificial intelligence for precision diagnostics. Its core business spans genomics testing -- including oncology and hereditary diagnostics -- and data services that leverage a vast clinical-molecular database. The company's offerings help clinicians make more informed treatment decisions by integrating laboratory data with clinical histories and other medical information. Recently, Tempus AI has prioritized scaling its platform and deepening integrations with healthcare institutions. Strategic collaborations, especially with large pharmaceutical companies, have been central to driving growth and product development. The company's ability to harness AI for intelligent diagnostics and to scale its proprietary data sets underpins its long-term competitive positioning. Key success factors include expanding its genomics testing volume, offering differentiated AI-driven products, and executing multi-year partnership deals that generate recurring revenue. Quarterly Highlights and Key Developments The quarter saw a pronounced surge in both genomics and data services revenue. Genomics, which covers specialized diagnostic tests for cancer and inherited conditions, reached $241.8 million in GAAP revenue, a jump of 115.3% compared to Q2 2024. Oncology testing, a product line that analyzes patient tumor genetics for therapy selection, delivered $133.2 million in sales on unit growth near 26%, reflecting a re-acceleration from the previous quarter. Hereditary testing, performed through the company's Ambry Genetics acquisition, contributed $97.3 million and grew units by about 32% over a pro forma prior-year comparison. Tempus AI delivered more than 212,000 next-generation sequencing (NGS) tests, up 30% from the year-ago quarter, indicating strong clinical demand. Data and services revenue, which encompasses products like Insights (data licensing for pharma partners), reached $72.8 million -- up 35.7% (GAAP). Insights alone increased 40.7% year-over-year. The company cited continued multi-year contract wins as a foundation, including a $200 million, three-year agreement with AstraZeneca and Pathos to build a large AI model for oncology. The forward contract value for data services (Total Remaining Contract Value) exceeded $1 billion as of April 30, 2025. The company reported gross profit (GAAP) of $195.0 million, with gross margins (GAAP) climbing to 62.0% from 45.5% in Q2 2024. Genomics gross margin (non-GAAP) increased from 49.4% in Q2 2024 to 59.4%. Data and services gross margin (GAAP) also edged up. Operating expenses declined as a percent of revenue, delivering much narrower operating losses and driving adjusted EBITDA closer to breakeven. The reported net loss decreased significantly from the prior year. From a product standpoint, several AI-enabled diagnostics advanced. Tempus Next is a clinical decision support tool that uses AI to help guide therapy for breast cancer, now rolled out to broader oncology segments. Tempus One, an AI clinical assistant, integrated into leading electronic health records to enhance workflow. The company also launched Tempus xM, a liquid biopsy test designed to monitor minimal residual disease and assess treatment response in advanced cancer. These initiatives were supported by a database now comprising over 40 million patient records, more than 350 petabytes of clinical and molecular data, and over 4,500 healthcare system integrations as of Q2 2025 -- providing a historical and artificial intelligence advantage in future product launches. Financial strength was boosted just after Q2 2025 by a $750 million convertible notes offering, replacing more expensive debt and increasing flexibility for future investments in AI compute resources and new diagnostics. Cash and securities stood at $293.0 million at quarter-end. No dividend was declared; TEM does not currently pay a dividend. The company reported ongoing progress toward securing regulatory reimbursement for new diagnostic assays, which could support further revenue growth if approvals come through. Outlook and What to Watch Next Management raised its full-year 2025 outlook, increasing revenue guidance to $1.26 billion and adjusted EBITDA guidance to $5 million. It now expects revenue of $1.26 billion for full year 2025, up from $1.25 billion previously, and adjusted EBITDA profitability of $5 million, an improvement of $110 million over fiscal 2024. This marks a milestone, as achieving profitability on an adjusted EBITDA basis in full year 2025 was a stated goal for the company's first decade. Investors should watch for continued volume growth in genomics testing, further progress on AI product launches, expansion of large-scale data partnerships, and success in securing regulatory reimbursement for newer assays such as liquid biopsy. The company indicated ongoing investments in its database, clinical integration capacity, and AI foundation model development as priorities. While the period demonstrated strong operational execution, ongoing integration of new business units, management of large contract risk, and further improvement in margin profile remain points of focus for upcoming quarters. No additional formal quantitative guidance was offered beyond the updated full-year targets. TEM does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.

Why Tempus AI Stock Jumped Today | The Motley Fool

Second-quarter results arrived with numbers that caused investors to feel increasingly bullish. The stock of Tempus AI (TEM 3.63%) gave back some of its gains after surging early in Friday's trading, but it still ended the daily session solidly in the green. The healthcare artificial intelligence (AI) company's share price ended Friday's trading up 3.6% but had been up 11.9% earlier in the session. Tempus AI delivered its second-quarter report before the market opened this morning, and sales and earnings for the period topped Wall Street's expectations. In addition to performance beats in the quarter, the company raised its full-year sales guidance. The company saw an adjusted loss of $0.22 per share on revenue of $314.6 million in the second quarter. The average Wall Street analyst estimate had targeted an adjusted per-share loss of $0.25 on sales of roughly $297.8 million. Sales increased roughly 90% year over year and far surpassed Wall Street's expectations, with strong momentum for the company's genomics segment powering huge growth. The stock gave back some of its early gains as today's trading progressed, but the healthcare AI software specialist delivered a strong quarterly report. In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this year. The company now expects full-year revenue to come in at roughly $1.26 billion, up from its previous target for sales of $1.26 billion. The new target suggests annual sales growth of roughly 86%. The company also said that it anticipates posting adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $5 million this year -- representing a $110 million improvement over last year's performance. With strong sales growth and signs of improving margins, Tempus AI could be on track to deliver strong results for long-term shareholders.

Tempus AI: Q2 Earnings Mark a Turning Point in AI-Powered Healthcare Strategy | Investing.com UK

Tempus AI Inc (NASDAQ:TEM) has released its financial results for the second quarter of 2025, showcasing significant growth in revenue and improved adjusted EBITDA. The company is also optimistic about its future financial performance, as reflected in its updated guidance. Tempus AI, Inc. has reported impressive financial results for the second quarter of 2025, marking a period of substantial growth and improved financial health. The company recorded a revenue of $314.6 million, an 89.6% increase from the same period last year. This figure significantly surpasses the expected revenue of $297.8 million. The company's gross profit also saw a remarkable increase of 158.3%, reaching $195.0 million compared to $75.5 million in the second quarter of 2024. Tempus AI's net loss for the quarter was $42.8 million, a significant improvement from the $552.2 million net loss recorded in the same quarter of the previous year. The net loss per share was $0.25, aligning with expectations and showing a stark improvement from the $6.86 loss per share in Q2 2024. The adjusted EBITDA for the quarter was a negative $5.6 million, a notable improvement from the negative $31.2 million reported in the second quarter of 2024. Eric Lefkofsky, Founder and CEO of Tempus, highlighted the company's performance, noting the growth in clinical volumes and the delivery of over 212,000 NGS tests during the quarter. The company's leadership in artificial intelligence and its progress towards building the largest foundation model in oncology were also key factors in its success. The company's genomics revenue, which increased by 115.3% year-over-year to $241.8 million, played a significant role in driving overall revenue growth. Looking ahead, Tempus AI has raised its full-year 2025 revenue guidance to approximately $1.26 billion, reflecting an anticipated 82% annual growth. The company also expects an adjusted EBITDA of $5 million for the full year, representing an improvement of approximately $110 million over 2024. This optimistic outlook is supported by Tempus AI's strategic initiatives and financial flexibility. Tempus AI's recent issuance of $750 million of 0.75% convertible senior notes has enhanced its balance sheet, allowing the company to replace a portion of its existing term loan with a lower interest debt instrument. The company ended the quarter with $293.0 million in cash and marketable securities, marking an improvement of approximately $70 million over the previous quarter. Tempus AI continues to expand its AI-powered clinical tools, extending its Tempus Next™ care pathway intelligence platform into breast cancer and integrating its Tempus One™ AI clinical assistant into leading electronic health record systems. These advancements, along with the introduction of Tempus xM™ for treatment and response monitoring, demonstrate the company's commitment to innovation and its potential for sustained growth. *** Looking to start your trading day ahead of the curve?